CTP-499 is a selective PDE inhibitor and deuterium-containing agent that slows the progression of type 2 diabetic kidney disease in patients with macroalbuminuria. CTP-499 is an HDX analogue and a pentoxifylline metabolite. Initial testing showed that CTP-499 slowed the negative processes in diabetic kidney disease. Concert is developing the agent as a complementary treatment along with the standard of care, angiotensin modulation with an ACEi or ARB. References: Perez-Gomez MV, Sanchez-Nino MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B. Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review. PubMed PMID: 26239562; PubMed Central PMCID: PMC4485003.

纯度：≥98%

CAS：1268605-91-9